Business Wire

Wisdom Launches New Short-form Audio Format ‘Voice Answers’ in Bid to Solve Social Audio’s Biggest Challenge

22.11.2022 14:17:00 EET | Business Wire | Press release

Share

Wisdom, a social audio app that facilitates one-to-one meaningful conversations, today launches a pioneering new format, ‘Voice Answers’, an asynchronous short-form audio take on the traditional questions and answers format.

Voice Answers was designed to overcome the limitations associated with the live social audio format, popularised by Clubhouse. Now the centerpiece of the app, ‘Voice Answers’ delivers an algorithmically curated feed of wise answers to self-discovery questions like “Describe your idea of a perfect day.” to mentoring questions like “How do I break into the film industry?” to life hack questions like “How do I set boundaries in a relationship?”

Social Audio has demonstrated tremendous promise, with platforms like Clubhouse, Spotify, Twitter, Discord and LinkedIn rolling out social audio experiences to hundreds of millions of users. However, social audio has recently been much maligned, with recent headlines including “Is social audio already dead?” and “The Rise And Fall Of Social Audio.”

Dayo Akinrinade founder and CEO of Wisdom comments: “The biggest challenge with social audio today is its low listening value-to-word ratio. While podcasts are carefully planned and produced, social audio tends to be more freewheeling and, as a result, the content quality is less reliable. Another challenge is the consumption of live audio content being limited to whomever happens to be listening at a given time. Inspired by TikTok’s content-first algorithm and short-video format, my goal with Voice Answers' asynchronous short-form audio format, is to bring elements of TikTok’s innovation to social audio by preserving the excitement of live conversations, whilst also solving the low listening value-to-word ratio problem that's endemic to the live social audio format that Clubhouse pioneered.”

With today’s launch of Voice Answers, the Wisdom app opens to a voice answer, which the user can listen to or swipe. Each swipe informs the machine-learning algorithm, helping improve content recommendations to provide a stream of personalised, high-quality answers.

To be creator-friendly, Voice Answers are restricted to less than 60 seconds and Wisdom auto-generates an audiogram for each Voice Answer, which creators can easily share on other social networks.

Dayo continues: “Questions and answers are powerful tools to unlock insights and gain a deeper understanding of who we are and the world around us. Early in my career, as a black woman in tech, I lacked access to wise people, which hampered my progression. The Voice Answers format is positioned to empower us to share our wisdom with the world, whilst simultaneously pioneering a new short form asynchronous audio format which I hope will overcome the current challenges associated with social audio.”

Download Wisdom for Android on Google Play store here
Download Wisdom for iOS on Apple App Store here

—---- END PRESS RELEASE —--

Notes to the Editor
A selection of supporting hi-res feature images can be found on Google Drive here

About Wisdom
Wisdom is a venture-backed social audio app on a mission to leave the world a bit wiser than we found it. Wisdom connects you for live one-to-one conversations and Q&A, centered on knowledge-sharing and self-discovery. Within a year of launch, Wisdom was awarded Apple’s App Store ‘App of the Day’ twice and TechRadar’s ‘Best Android Apps of 2022’.

Wisdom is a pioneer in the social audio space having created ‘Voice Answers’ an asynchronous, short-form audio take on the traditional Q&A format, which delivers an algorithmically curated feed of high-quality voice answers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Danielle Zhu or Sarah Herrera from Thinking Hat PR:
danielle@thinkinghatpr.com
sarahh@thinkinghatpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye